Sankari Durairajan

Sankari Durairajan

Auto-generated profile, based on publicly available information

Sankari Durairajan

Department of Biotechnology, Faculty of Biomedical Sciences, Technology and Research, Sri Ramachandra Institute of Higher Education and Research (Deemed to be University), Chennai, India

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2020 in Expert Review of Molecular Diagnostics
Verified
Journal Article
Closed access
CWCharles Emmanuel Jebaraj Walter
Charles Emmanuel Jebaraj Walter
SDSankari Durairajan
Sankari Durairajan
KPKalaiselvi Periyandavan
Kalaiselvi Periyandavan
George Priya Doss C.George Priya Doss C.
George Priya Doss C.
DGDicky John Davis G
Dicky John Davis G
HZHatem Zayed
Hatem Zayed
Introduction: Bladder cancer is the second most common genitourinary tract cancer and is often recurrent and/or chemoresistant after tumor resection. Cigarette smoking, exposure to aromatic amines, and chronic infection/inflammation are bladder cancer risk factors. NF-κB is a transcription factor that plays a critical role in normal physiology and bladder cancer. Bladder cancer patients have constitutively active NF-κB triggered by pro-inflammatory cytokines, chemokines, and hypoxia, augmenting carcinogenesis and progression. Areas covered: NF-κB orchestrates protein interactions (PTEN, survivin, VEGF), regulation (CYLD, USP13) and gene expression (Trp 53) resulting in bladder cancer progression, recurrence and resistance to therapy. This review focuses on NF-κB in bladder inflammation, cancer and resistance to therapy. Expert opinion: NF-κB and bladder cancer necessitate further research to develop better diagnostic and treatment regimens that address progression, recurrence and resistance to therapy. NF-κB is a master regulator that can act with or on minimally one cancer hallmark gene or protein, leading to bladder cancer progression (Tp53, PTEN, VEGF, HMGB1, CYLD, USP13), recurrence (PCNA, BcL-2, JUN) and resistance to therapy (P-gp, twist, SETD6). Thus, an understanding of bladder cancer in relation to NF-κB will offer improved strategies and efficacious targeted therapies resulting in minimal progression, recurrence and resistance to therapy.

1 September 2014 in Experimental Gerontology
Verified
Journal Article
Closed access
TKThulasi Raman Krishnan
Thulasi Raman Krishnan
PVPrema Velusamy
Prema Velusamy
ASAshokkumar Srinivasan
Ashokkumar Srinivasan
TGThellamudhu Ganesan
Thellamudhu Ganesan
SMSuresh Mangaiah
Suresh Mangaiah
KPKalaiselvi Periandavan
Kalaiselvi Periandavan

13 September 2018 in PeerJ
Verified
Journal Article
Open access
PDF file
SDSankari Durairajan
Sankari Durairajan
CWCharles Emmanuel Jebaraj Walter
Charles Emmanuel Jebaraj Walter
MSMary Divya Samuel
Mary Divya Samuel
DPDinesh Palani
Dinesh Palani
DGDicky John Davis G
Dicky John Davis G
TJThanka Johnson
Thanka Johnson
Background Urothelial carcinoma (UC) is the fifth most common malignancy that accounts for 5% of all cancers. Diagnostic markers that predict UC progressions are inadequate. NF-κB contributes towards disease progression upon constitutive activation in many solid tumors. The nuclear localization of NF-κB indicates increased transcriptional activity while cytoplasmic localization indicates the inactive protein repository that can be utilized readily by a malignant cell. This study delineates the nuclear and cytoplasmic differential expression of NF-κB heterodimers in UC progression. Methods The involvement of the NF-κB proteins in UC was analyzed in silico using cytoscape. The expression of NF-κB heterodimers was analyzed by immunohistochemistry. Results PINA4MS app in cytoscape revealed over expression of RelA and suppression of NF-κB1 (p50 precursor) in UC whereas the expression of NF-κB target proteins remained unhindered. Immunohistochemical localization showed nuclear RelA/p50 in low grade UC whereas in high grade only RelA expression was observed. Conversely, cytoplasmic expression of RelA/p50 remained extensive across high and low grade UC tissues (p < 0.005). RelA nuclear and cytoplasmic expression (p < 0.005) was directly proportional to the disease progression. In our study, some of the high-grade UC tissues with squamous differentiation and muscle invasion had extensive nuclear p50 localization. The phenomenon of RelA/p50 expression seen increased in low-grade UC than high grade UC might be due to their interaction with other members of NF-κB family of proteins. Thus, NF-κB RelA/p50 differential expression may play a unique role in UC pathogenesis and can serve as a biomarker for diagnosis.

1 February 2020 in American Journal of Biochemistry and Biotechnology
Verified
Journal Article
Closed access
SDSankari Durairajan
Sankari Durairajan
CWCharles Emmanuel Jebaraj Walter
Charles Emmanuel Jebaraj Walter
KPKalaiselvi Periyandavan
Kalaiselvi Periyandavan
George Priya Doss C.George Priya Doss C.
George Priya Doss C.
DGDicky John Davis G
Dicky John Davis G
TJThanka Johnson
Thanka Johnson